Patents by Inventor Michael M. Dubreuil

Michael M. Dubreuil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20220193139
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
    Patent number: 11304978
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 19, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPY
    Publication number: 20210085720
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a knockout of the expression of the TET2 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
    Publication number: 20210085721
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff